The New York Times has uncovered a confidential government report that recommends that the anti-diabetes drug Avandia (rosiglitazone) be removed from the market because of link to heart attacks and heart failure.
The New York Times has uncovered a confidential government report that recommends that the anti-diabetes drug Avandia (rosiglitazone) be removed from the market because of link to heart attacks and heart failure.
